Navigation Links
Favorable Demographics Will Drive Moderate Expansion In The US Market For Skin Replacements And Substitutes
Date:7/30/2013

TORONTO, July 30, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the United States market for skin replacements and substitutes will see moderate market expansion, driven primarily by favorable demographics. However, a lack of clinical support will somewhat limit this market over the next few years.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36799LOGO )

Favorable demographics will drive increased use of both biosynthetic skin replacements and biological skin substitutes through 2021 as the elderly, obese and diabetic populations expand in the US. Individuals in these groups are more prone to developing chronic wounds, which will drive adoption of these products.

This market will, however, continue to face competition from products such as moist wound dressings and negative pressure wound therapy (NPWT) devices, which are considered first-line treatments for most chronic wounds. On a per-unit basis, these alternative treatments are often far less expensive than skin replacements and substitutes, and as a result they will continue to be attractive to cost-conscious facilities.

"Companies will need to invest in additional clinical trials in order to encourage greater adoption of their products," said MRG Analyst Daniel Brown. "Given that alternative treatments are often less costly, physicians and facilities will want to see clinical evidence supporting the efficacy of skin replacements and substitutes. The lack of strong clinical evidence will limit this market for the next few years, but the publication of trials that are currently in progress will eventually lead to stronger product adoption, pending positive results."

MiMedx Group's EpiFix biosynthetic product, which was launched in 2012, will see particularly strong adoption through 2021. This product is a unique nonliving amniotic allograft-derived biosynthetic skin replacement that can purportedly be used for a wide range of indications at a lower per-treatment cost than other major products on the market. In particular, the injectable version of the EpiFix will see rapid revenue growth because this product is easy to use and effective for treating wounds that would otherwise be difficult to navigate. MiMedx currently has two studies underway in an effort to have the products approved for reimbursement under Medicare, which will further encourage adoption should the trials prove successful.

Millennium Research Group's US Markets for Skin Replacements and Substitutes 2013 report includes unit, average selling price and revenue information, along with market drivers and limiters and a competitive landscape for biological skin substitutes and biosynthetic skin replacements in the United States.

About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources Group company (www.DecisionResourcesGroup.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Christopher Comfort
Decision Resources Group
781-993-2597
ccomfort@dresources.comAlex Jablokow
Millennium Research Group
617-599-8613
ajablokow@mrg.net


'/>"/>
SOURCE Millennium Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. OrbusNeichs Combo Dual Therapy Stent™ Demonstrates Favorable Clinical and Safety Outcomes at 12-Month Follow-Up
2. Favorable Scenario for Japan Pharma Industry in Coming Years, New Report Says
3. Upsher-Smith Presents Favorable Phase I Data For USL261, A Novel Formulation Of Intranasal Midazolam, At 65th Annual Meeting Of The American Academy Of Neurology
4. A nano car with molecular 4-wheel drive
5. ResearchMoz: Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market
6. Compressus Drives Programmable Workflow And Unprecedented Flexibility With Introduction of MEDxConnect™ v4.0
7. Slovenias 1st Total Artificial Heart Patient Discharged from UMC Ljubljana Using the Freedom® Portable Driver
8. Micross Components Hosts Stop on "Drive for Innovation" Tour
9. Thomson Reuters Cortellis Drives Drug Discovery and Development With Powerful New Web Services
10. Roche Launches 454 Sequencing Assays for High Sensitivity Genetic Variant Detection in Leukemia Samples to Drive Blood Cancer Research Worldwide
11. Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... ANGELES , Feb. 16, 2017   ... ), a clinical-stage biotechnology company developing first-in-class biological ... announced that it has elected to terminate its ... natriuretic peptide receptor agonists, including Cenderitide. ... strategic move as we prioritize our efforts to ...
(Date:2/16/2017)... SAN DIEGO , Feb. 16, 2017 /PRNewswire/ ... and innovative products to treat a variety of ... $5 million Series 1a financing and entered into ... Bank (SVB).  Dermata intends to use the capital ... of making major advancements in the treatment of ...
(Date:2/16/2017)... , Feb. 16, 2017  Rhythm, ... rare genetic deficiencies that result in life-threatening ... a $41 million mezzanine round of financing ... OrbiMed, MPM Capital, New Enterprise Associates, Pfizer ... undisclosed public healthcare investment fund. Rhythm will ...
(Date:2/15/2017)... ... 15, 2017 , ... Park Systems , a leader in Atomic Force ... that drastically boosts productivity with single click reliable nanoscale images, is now available on ... up and taking the image once done manually by the operator producing high quality ...
Breaking Biology Technology:
(Date:2/13/2017)... 2017  RSA Conference -- RSA, a Dell Technologies ... to enhance fraud detection and investigation across digital ... Fraud & Risk Intelligence Suite. The new platform ... insights from internal and external sources as well ... customers from targeted cybercrime attacks. "Fraudsters ...
(Date:2/10/2017)... Research and Markets has announced the addition ... and Commercial Aspects" to their offering. ... Biomarkers play an ... for selection of treatment as well for monitoring the results. ... in modern medicine. Biochip/microarray technologies and next generation sequencing are ...
(Date:2/8/2017)... NEW YORK , Feb. 8, 2017 /PRNewswire/ ... an individual,s voice to match it against a ... voice such as pitch, cadence, and tone are ... systems require minimal hardware installation, as most PCs ... remotely for different transactions. Voice recognition biometrics are ...
Breaking Biology News(10 mins):